RESUMEN
BACKGROUND: This study analyzed the immunoexpression of calcitonin receptor (CTR) and glucocorticoid receptor (GR) in central giant cell lesions (CGCLs) and verified potential associations with patient's response to clinical treatment with intralesional injection of triamcinolone. MATERIALS AND METHODS: Fifty-four cases of CGCLs, including 22 non-aggressive, and 32 aggressive, were investigated by immunohistochemistry. RESULTS: Surgery was the therapeutic choice for 53.1% of the aggressive CGCLs, and 46.9% were submitted to the conservative treatment with intralesional triamcinolone injections. Among patients submitted to conservative treatment, 60% (n = 9) showed favorable response. CTR expression was observed in 68.51%, and GR in 94.44% of the total sample. There were no differences in the expression of CTR, neither GR in mononucleated stromal cells (MSCs) or multinucleated giant cells (MGCs), in relation to aggressiveness, treatment performed for and the response to conservative treatment. Both markers showed a positive correlation between their expression in MSCs and MGCs in the total sample (P < 0.0001). CTR expression on MSCs showed a positive correlation with MGCs in the aggressive and non-aggressive groups (P < 0.0001). CONCLUSIONS: Calcitonin receptor and GR expression were diffuse and similar in non-aggressive and aggressive cases, and it did not influence the response to clinical treatment with triamcinolone in the sample studied.
Asunto(s)
Células Gigantes/metabolismo , Granuloma de Células Gigantes/tratamiento farmacológico , Granuloma de Células Gigantes/metabolismo , Inmunohistoquímica , Enfermedades Maxilomandibulares/tratamiento farmacológico , Enfermedades Maxilomandibulares/metabolismo , Receptores de Calcitonina/metabolismo , Receptores de Glucocorticoides/metabolismo , Triamcinolona , Adolescente , Adulto , Niño , Femenino , Expresión Génica , Humanos , Inyecciones Intralesiones , Masculino , Persona de Mediana Edad , Receptores de Calcitonina/genética , Receptores de Glucocorticoides/genética , Estudios Retrospectivos , Resultado del Tratamiento , Adulto JovenRESUMEN
Osteoporosis is a chronic disease that impairs proper bone remodeling. Guided bone regeneration is a surgical technique that improves bone defect in a particular region through new bone formation, using barrier materials (e.g. membranes) to protect the space adjacent to the bone defect. The polytetrafluorethylene membrane is widely used in guided bone regeneration, however, new membranes are being investigated. The purpose of this study was to evaluate the effect of P(VDFTrFE)/BT [poly(vinylidene fluoride-trifluoroethylene)/barium titanate] membrane on in vivo bone formation. Twenty-three Wistar rats were submitted to bilateral ovariectomy. Five animals were subjected to sham surgery. After 150 days, bone defects were created and filled with P(VDF-TrFE)/BT membrane or PTFE membrane (except for the sham and OVX groups). After 4 weeks, the animals were euthanized and calvaria samples were subjected to histomorphometric and computed microtomography analysis (microCT), besides real time polymerase chain reaction (real time PCR) to evaluate gene expression. The histomorphometric analysis showed that the animals that received the P(VDF-TrFE)/BT membrane presented morphometric parameters similar or even better compared to the animals that received the PTFE membrane. The comparison between groups showed that gene expression of RUNX2, BSP, OPN, OSX and RANKL were lower on P(VDF-TrFE)/BT membrane; the gene expression of ALP, OC, RANK and CTSK were similar and the gene expression of OPG, CALCR and MMP9 were higher when compared to PTFE. The results showed that the P(VDF-TrFE)/BT membrane favors bone formation, and therefore, may be considered a promising biomaterial to support bone repair in a situation of osteoporosis.
Asunto(s)
Compuestos de Bario/química , Hidrocarburos Fluorados/química , Osteogénesis , Osteoporosis/cirugía , Titanio/química , Compuestos de Vinilo/química , Animales , Materiales Biocompatibles/química , Regeneración Ósea , Trasplante Óseo , Huesos/metabolismo , Catepsina K/metabolismo , Modelos Animales de Enfermedad , Femenino , Perfilación de la Expresión Génica , Regulación de la Expresión Génica , Metaloproteinasa 9 de la Matriz/metabolismo , Membranas Artificiales , Osteoblastos/metabolismo , Osteoclastos/metabolismo , Osteoporosis/metabolismo , Ligando RANK/metabolismo , Ratas , Ratas Wistar , Reacción en Cadena en Tiempo Real de la Polimerasa , Receptor Activador del Factor Nuclear kappa-B/metabolismo , Receptores de Calcitonina/metabolismo , Microtomografía por Rayos XRESUMEN
OBJECTIVE: To evaluate the expression of glucocorticoid receptor (GR), calcitonin receptor (CTR), and osteocalcin (OC) in aggressive and nonaggressive central giant cell lesions (CGCLs). The numbers of mitotic and multinucleated giant cells were also evaluated. STUDY DESIGN: Thirty-one cases of CGCL were submitted for immunohistochemistry. Mitotic figures and multinucleated giant cells were assessed through histochemical analyses. RESULTS: Positive staining for GR, CTR, and OC was observed in all cases studied. There were no differences between CGCL variants with regard to the expression of GR, CTR, or OC. The aggressive group showed a higher number of multinucleated giant cells compared with the nonaggressive group (P < .05). CONCLUSIONS: Nonaggressive and aggressive CGCLs cannot be distinguished by OC, CTR, or GR expression, although the number of multinucleated giant cells may help differentiate between CGCL types.
Asunto(s)
Tumor Óseo de Células Gigantes/metabolismo , Tumor Óseo de Células Gigantes/patología , Neoplasias Maxilomandibulares/metabolismo , Neoplasias Maxilomandibulares/patología , Osteocalcina/metabolismo , Receptores de Calcitonina/metabolismo , Receptores de Glucocorticoides/metabolismo , Adulto , Biomarcadores de Tumor/metabolismo , Femenino , Humanos , Técnicas para Inmunoenzimas , MasculinoRESUMEN
The aim was to evaluate the phenotypic expression of various cellular osteotropic factors in central giant cell granuloma (CGCG). Paraffin-embedded tissue from 27 aggressive and 10 non-aggressive cases of CGCG was assessed for the expression of RANK, GRalpha and CTR using immunohistochemistry. In addition, a staining-intensity-distribution (SID) score (proportion of stained cells x staining intensity) was used to assess immunoreactivity of each marker. The results showed that the multinucleated giant cells (MGC), mononuclear stromal cells (MSC) and endothelial cells were intensely positives for GRalpha, moderate for RANK and weak-to-moderate for CTR in all clinical groups, whereas spindle-shaped cells were intensely immunoreactive to GRalpha and unreactive to CTR and RANK. Although neither difference in RANK and GRalpha expression nor the SID score between the clinical forms of CGCG was observed, a statistically significant difference for CTR was evident. Furthermore, the comparison of the marker expression and SID score showed a significant correlation for all three markers within the clinical groups, except for GRalpha in the non-aggressive lesions where a weak and no significant correlation was detected. It was concluded that although the MGC share some similarities with the osteoclasts, they demonstrate phenotypic differences from each other that suggest a distinct precursor. The expression of RANK, GRalpha and CTR also suggest a role for these receptors in the resorptive activity of different cellular groups in CGCG and may lead to a more effective use of therapeutic inhibitors of bone resorption for the treatment of these disorders.